Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 3
2014 2
2015 4
2016 3
2017 1
2018 3
2019 1
2020 3
2021 6
2022 2
2023 5
2024 4
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variants.
Carconi C, Bosi C, Scartozzi M, Cergnul M, Cinausero M, Faloppi L, Garajova I, Lonardi S, Pecora I, Pisanu L, Spadi R, Spallanzani A, Peretti U, Macchini M, Orsi G, Reni M. Carconi C, et al. Among authors: peretti u. Pancreatology. 2024 Nov;24(7):1066-1072. doi: 10.1016/j.pan.2024.09.006. Epub 2024 Sep 12. Pancreatology. 2024. PMID: 39277480
Exploring external validity of chemotherapy for pancreatic ductal adenocarcinoma in real life.
Reni M, Giordano G, Audisio M, Orsi G, Macchini M, Gobba SM, Rapposelli I, Lucenti A, Luchena G, Faloppi L, Zustovich F, Ricci V, Cergnul M, Formica V, Procaccio L, Baccolini V, Briccolani A, Cascinu S, Peretti U. Reni M, et al. Among authors: peretti u. Dig Liver Dis. 2025 Jan;57(1):104-110. doi: 10.1016/j.dld.2024.06.025. Epub 2024 Jul 14. Dig Liver Dis. 2025. PMID: 39003164 Clinical Trial.
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer.
Pilotto S, Novello S, Peretti U, Kinspergher S, Ciuffreda L, Milella M, Carbognin L, Vavalà T, Ferrara R, Caccese M, Tortora G, Bria E. Pilotto S, et al. Among authors: peretti u. Expert Opin Investig Drugs. 2015;24(9):1143-61. doi: 10.1517/13543784.2015.1056341. Epub 2015 Jun 12. Expert Opin Investig Drugs. 2015. PMID: 26065529 Review.
Tubulin inhibitors in non-small cell lung cancer: looking back and forward.
Ferrara R, Pilotto S, Peretti U, Caccese M, Kinspergher S, Carbognin L, Karachaliou N, Rosell R, Tortora G, Bria E. Ferrara R, et al. Among authors: peretti u. Expert Opin Pharmacother. 2016 Jun;17(8):1113-29. doi: 10.1517/14656566.2016.1157581. Epub 2016 Mar 10. Expert Opin Pharmacother. 2016. PMID: 26898217 Review.
Predictors of outcome for patients with lung adenocarcinoma carrying the epidermal growth factor receptor mutation receiving 1st-line tyrosine kinase inhibitors: Sensitivity and meta-regression analysis of randomized trials.
Pilotto S, Di Maio M, Peretti U, Kinspergher S, Brunelli M, Massari F, Sperduti I, Giannarelli D, De Marinis F, Tortora G, Bria E. Pilotto S, et al. Among authors: peretti u. Crit Rev Oncol Hematol. 2014 May;90(2):135-45. doi: 10.1016/j.critrevonc.2013.11.005. Epub 2013 Dec 1. Crit Rev Oncol Hematol. 2014. PMID: 24332915 Review.
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv).
Orsi G, Cavaliere A, Tortora G, Lonardi S, Macchini M, Di Marco M, Giordano G, Vasile E, Scartozzi M, Bozzarelli S, Noventa S, Rodriquenz MG, Militello AM, Rapposelli IG, Garajova I, De Lorenzo S, Merelli B, Bittoni A, Salvatore L, Procaccio L, Paratore C, Spallanzani A, Peretti U, Niger M, Giommoni E, Bernardini I, Tamburini E, Bernardino K, Forti L, Valente MM, Cascinu S, Milella M, Reni M. Orsi G, et al. Among authors: peretti u. Br J Cancer. 2023 Mar;128(5):877-885. doi: 10.1038/s41416-022-02086-w. Epub 2022 Dec 8. Br J Cancer. 2023. PMID: 36482190 Free PMC article.
31 results